Optimizing oncolytic virotherapy in cancer treatment von Harrington, Kevin, Freeman, Daniel J., Kelly, Beth, Harper, James, Soria, Jean-Charles

Volltext

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer von AMADO, Rafael G, WOLF, Michael, PATTERSON, Scott D, CHANG, David D, PEETERS, Marc, VAN CUTSEM, Eric, SIENA, Salvatore, FREEMAN, Daniel J, JUAN, Todd, SIKORSKI, Robert, SUGGS, Sid, RADINSKY, Robert

Volltext

Head-mounted central venous access during optical recordings and manipulations of neural activity in mice von Liu, Christine, Freeman, Daniel J., Lammel, Stephan

Volltext

Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer von Freeman, Daniel J, McDorman, Kevin, Ogbagabriel, Selam, Kozlosky, Carl, Yang, Bing-Bing, Doshi, Sameer, Perez-Ruxio, Juan Jose, Fanslow, William, Starnes, Charlie, Radinsky, Robert

Volltext

Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1(+) Activated T Cells von Dovedi, Simon J., Elder, Matthew J., Yang, Chunning, Sitnikova, Suzanne, Irving, Lorraine, Hansen, Anna, Hair, James, Jones, Des C., Hasani, Sumati, Wang, Bo, Im, Seock-Ah, Tran, Ben, Subramaniam, Deepa S., Gainer, Shelby D., Vashisht, Kapil, Lewis, Arthur, Jin, Xiaofang, Kentner, Stacy, Mulgrew, Kathy, Wang, Yaya, Overstreet, Michael G., Dodgson, James, Wu, Yanli, Palazon, Asis, Morrow, Michelle, Rainey, Godfrey J., Browne, Gareth J., Neal, Frances, Murray, Thomas, Toloczko, Aleksandra D., Dall'Acqua, William, Achour, Ikbel, Freeman, Daniel J., Wilkinson, Robert W., Mazor, Yariv

Volltext

PTEN Regulates Mdm2 Expression through the P1 Promoter von Chang, Chun-Ju, Freeman, Daniel J, Wu, Hong

Volltext

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced... von Mendell, Jeanne, Freeman, Daniel J., Feng, Wenqin, Hettmann, Thore, Schneider, Matthias, Blum, Sabine, Ruhe, Jens, Bange, Johannes, Nakamaru, Kenji, Chen, Shuquan, Tsuchihashi, Zenta, von Pawel, Joachim, Copigneaux, Catherine, Beckman, Robert A.

Volltext

A comparability study of 5 commercial KRAS tests von Oliner, Kelly, Juan, Todd, Suggs, Sid, Wolf, Michael, Sarosi, Ildiko, Freeman, Daniel J, Gyuris, Tibor, Baron, Will, Bakker, Andreas, Parker, Alex, Patterson, Scott D

Volltext

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer von Amado, Rafael G, Wolf, Michael, Peeters, Marc, Van Cutsem, Eric, Siena, Salvatore, Freeman, Daniel J, Juan, Todd, Sikorski, Robert, Suggs, Sid, Radinsky, Robert, Patterson, Scott D, Chang, David D

Volltext

Gene Expression Profiles Can Predict Panitumumab Monotherapy Responsiveness in Human Tumor Xenograft Models von Boedigheimer, Michael J, Freeman, Daniel J, Kiaei, Panteha, Damore, Michael A, Radinsky, Robert

Volltext

Augmentation of Radiation Response by Panitumumab in Models of Upper Aerodigestive Tract Cancer von Kruser, Tim J., M.D, Armstrong, Eric A., M.S, Ghia, Amol J., M.D, Huang, Shyhmin, Ph.D, Wheeler, Deric L., Ph.D, Radinsky, Robert, Ph.D, Freeman, Daniel J., Ph.D, Harari, Paul M., M.D

Volltext

Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor von Freeman, Daniel J, Bush, Tammy, Ogbagabriel, Selam, Belmontes, Brian, Juan, Todd, Plewa, Cherylene, Van, Gwyneth, Johnson, Carol, Radinsky, Robert

Volltext

Azole-based inhibitors of AKT/PKB for the treatment of cancer von Zeng, Qingping, Allen, John G., Bourbeau, Matthew P., Wang, Xianghong, Yao, Guomin, Tadesse, Seifu, Rider, James T., Yuan, Chester C., Hong, Fang-Tsao, Lee, Matthew R., Zhang, Shiwen, Lofgren, Julie A., Freeman, Daniel J., Yang, Suijin, Li, Chun, Tominey, Elizabeth, Huang, Xin, Hoffman, Douglas, Yamane, Harvey K., Fotsch, Christopher, Dominguez, Celia, Hungate, Randall, Zhang, Xiaoling

Volltext

PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms von Freeman, Daniel J., Li, Andrew G., Wei, Gang, Li, Heng-Hong, Kertesz, Nathalie, Lesche, Ralf, Whale, Andrew D., Martinez-Diaz, Hilda, Rozengurt, Nora, Cardiff, Robert D., Liu, Xuan, Wu, Hong

Volltext

A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer von Crawford, Jeffrey, Swanson, Paul, Schwarzenberger, Paul, Sandler, Alan, Prager, Diane, Zhang, Kathy, Freeman, Daniel J., Johnson, Carol W., Krishnan, Kartik, Johnson, David

Volltext

Association of K- ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone von Freeman, Daniel J, Juan, Todd, Reiner, Maureen, Hecht, J. Randolph, Meropol, Neal J, Berlin, Jordan, Mitchell, Edith, Sarosi, Ildiko, Radinsky, Robert, Amado, Rafael G

Volltext

Structure–Activity Relationships of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Investigations of Various 6,5-Heterocycles to Improve Met... von Stec, Markian M, Andrews, Kristin L, Booker, Shon K, Caenepeel, Sean, Freeman, Daniel J, Jiang, Jian, Liao, Hongyu, McCarter, John, Mullady, Erin L, San Miguel, Tisha, Subramanian, Raju, Tamayo, Nuria, Wang, Ling, Yang, Kevin, Zalameda, Leeanne P, Zhang, Nancy, Hughes, Paul E, Norman, Mark H

Volltext

Selective Class I Phosphoinositide 3‑Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511 von Norman, Mark H, Andrews, Kristin L, Bo, Yunxin Y, Booker, Shon K, Caenepeel, Sean, Cee, Victor J, D’Angelo, Noel D, Freeman, Daniel J, Herberich, Bradley J, Hong, Fang-Tsao, Jackson, Claire L. M, Jiang, Jian, Lanman, Brian A, Liu, Longbin, McCarter, John D, Mullady, Erin L, Nishimura, Nobuko, Pettus, Liping H, Reed, Anthony B, Miguel, Tisha San, Smith, Adrian L, Stec, Markian M, Tadesse, Seifu, Tasker, Andrew, Aidasani, Divesh, Zhu, Xiaochun, Subramanian, Raju, Tamayo, Nuria A, Wang, Ling, Whittington, Douglas A, Wu, Bin, Wu, Tian, Wurz, Ryan P, Yang, Kevin, Zalameda, Leeanne, Zhang, Nancy, Hughes, Paul E

Volltext

Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases von Smith, Adrian L, D’Angelo, Noel D, Bo, Yunxin Y, Booker, Shon K, Cee, Victor J, Herberich, Brad, Hong, Fang-Tsao, Jackson, Claire L. M, Lanman, Brian A, Liu, Longbin, Nishimura, Nobuko, Pettus, Liping H, Reed, Anthony B, Tadesse, Seifu, Tamayo, Nuria A, Wurz, Ryan P, Yang, Kevin, Andrews, Kristin L, Whittington, Douglas A, McCarter, John D, Miguel, Tisha San, Zalameda, Leeanne, Jiang, Jian, Subramanian, Raju, Mullady, Erin L, Caenepeel, Sean, Freeman, Daniel J, Wang, Ling, Zhang, Nancy, Wu, Tian, Hughes, Paul E, Norman, Mark H

Volltext

Synthesis and structure–activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold von Wurz, Ryan P., Liu, Longbin, Yang, Kevin, Nishimura, Nobuko, Bo, Yunxin, Pettus, Liping H., Caenepeel, Sean, Freeman, Daniel J., McCarter, John D., Mullady, Erin L., Miguel, Tisha San, Wang, Ling, Zhang, Nancy, Andrews, Kristin L., Whittington, Douglas A., Jiang, Jian, Subramanian, Raju, Hughes, Paul E., Norman, Mark H.

Volltext